Webinar

Optimising viral vector manufacturing with CDMO expertise and innovation

Available on-demand

60 Minutes

Viral vector manufacturing continues to face challenges in delivering consistent quality and achieving high productivity at scale. This webinar will highlight how CDMO innovation drives improvements across upstream and downstream processes and accelerates analytical development for lentiviral and adeno-associated virus (AAV) vectors. Discussion will cover strategies to enhance productivity, quality and yield, while addressing key bottlenecks in vector manufacturing. Participants will gain insights into the evolving approaches that are enabling more robust, flexible, and efficient viral vector manufacturing to support next-generation gene therapies. In this webinar, you'll learn more about:

Cutting-edge innovation technologies improving vector purity and productivity
A CDMO platform approach ensuring seamless integration of technologies and processes to drive performance
A rapid development of vector genome titre and gene expression assays within just 2 months

Speakers

Sébastien Ribault

Chief Business Officer

OXB

Dr. Sébastien Ribault joined OXB in 2022 as Chief Business Officer. He has over 25 years of experience across the biotechnology industry and CDMO space. Sébastien was previously at the Life Science business of Merck KGaA, Darmstadt, Germany where he was Vice President & Head of Biologics and Viral Vector CDMO, leading the CDMO Expansion project, establishing the Services business case and helping to establish the Life Science Services business unit. Prior to his 17 years with the Life Science business of Merck KGaA, Darmstadt, Germany, Sébastien was a Gene Therapy Development Scientist at Transgene and Head of the R&D Laboratory at Hemosystem. He has a PhD in Molecular and Cellular Biology from the University of Strasbourg.

Register here to watch on-demand!

Already registered? Click here to login.